丙二酰辅酶A脱羧酶缺乏症是英文疾病名称Malonyl-CoA decarboxylase deficiency的中文翻译,又叫丙二酸尿症,MCD缺乏症。丙二酰辅酶A脱羧酶缺乏症不能将某些脂肪转化为能量。通常在儿童早期发病。几乎所有的患者都会发育迟缓。其他症状和体征可包括弱肌张力(低张力)、癫痫发作、腹泻、呕吐和低血糖。心脏病,称为心肌病,以...
PROBLEM TO BE SOLVED: To provide a new compound useful in treating certain metabolic diseases and diseases modulated by the inhibition of an enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD).ARRHENIUS THOMASアルヘニウス トーマス...
MALONYL COA-DECARBOXYLASE INHIBITOREN ALS STOFFWECHSELMODULATOREN 发明人: ARRHENIUS, THOMAS;CHEN, MI;CHENG, JIE FEI;HUANG, YUJIN;NADZAN, ALEX;TITH, SOVOUTHY;WALLACE, DAVID;LIU, BIN;NISHIMOTO, MASAHIRO;LOPASCHUK, GARY D.;DYCK, JASON R. 申请人: 申请日期: 2002-01-22 申请公布日期: 2007-08...
MCD malonyl-CoA decarboxylase NSPC neural stem/progenitor cells PM plasma membrane TGN trans-Golgi network VMH ventromedial hypothalamus 1. Introduction: an historical perspective Malonyl-CoA is the precursor of fatty acid (FA) synthesis and its levels fluctuate greatly in response to nutrients and ho...
Paralleling its role in promoting energy expenditure through FA disposal, PPAR[alpha] also inhibits the lipogenic pathway by induction of the malonyl-CoA decarboxylase which degrades malonyl-CoA, a precursor of FA biosynthesis and inhibitor of the mitochondrial transporter CPT-1 [31] (Figure 1). ...
Mulder, H. et al. Overexpression of a modified human malonyl-CoA decarboxylase blocks the glucose-induced increase in malonyl-CoA level but has no impact on insulin secretion in INS-1-derived (832/13) beta-cells.J. Biol. Chem.276, 6479–6484 (2001). ...
网络脱羧酶 网络释义 1. 脱羧酶 www.heporg.com|基于2个网页
Cheng, Jie FeiChen, MiArrhenius, ThomasLopaschuk, Gary D.Dyck, Jason R.Wilson, Mark E.Serafimov, RossyWOUS7449482 2004年7月28日 2008年11月11日 Chugai Seiyaku Kabushiki Kaisha Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors...
is a potent inhibitor ofmitochondrial respiration. A major role for ACSF3 is to provide a metabolic pathway for the clearance of malonate by the generation of malonyl-CoA, which can then be decarboxylated to acetyl-CoA by malonyl-CoAdecarboxylase. Additionally, ACSF3-derived malonyl-CoA can be...
In particular, this invention relates to the use of novel compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the formulae (I) and (II), wherein Y, C, R1,...